Announcement • Jun 10
Microport CardioFlow Appoints Hugues Gervais as Chief Commercial Officer,Effective May 18, 2026 MicroPort CardioFlow announced the appointment of Hugues Gervais as Chief Commercial Officer, effective May 18, 2026. He will lead MicroPort CardioFlow's global commercial strategy and execution as the company continues to expand its international presence and strengthen its position in the cardiovascular medical device market. Mr. Gervais is a seasoned international executive with more than 25 years in the cardiovascular medical device industry. He brings extensive expertise in strategy, marketing, business development, and commercial leadership, having held senior roles at leading global healthcare organizations. He has deep knowledge across both Structural Heart and Cardiac Rhythm Management. Over his career, Mr. Gervais has driven the international expansion of cardiovascular businesses, led major product launches, supported periods of accelerated growth, and built high-performing commercial teams in complex, highly regulated environments. As MicroPort CardioFlow brings together its Cardiac Rhythm Management and Structural Heart businesses, Mr. Gervais' global experience, strategic vision, and commercial leadership will be valuable assets in accelerating the company's international development and long-term growth. Announcement • Jun 05
Microport Cardioflow Medtech Corporation Announces Board and Committee Changes, Effective June 4, 2026 MicroPort CardioFlow Medtech Corporation announced that Ms. Wu Xia ("Ms. Wu") retired as a non-executive Director with effect from the conclusion of the AGM on June 4, 2026 and did not offer herself for re-election at the AGM as disclosed in the Circular. Accordingly, Ms. Wu ceased to act as a member of the commercialization committee (the "Commercialization Committee") of the Company with effect from the conclusion of the AGM. The Board is also pleased to announce that Mr. Mao Junxiang ("Mr. Mao") has been appointed as an independent non-executive Director and a member of the Commercialization Committee, with effect from June 4, 2026. The biographical details of Mr. Mao are set out below: Mr. Mao, aged 54, has more than 30 years of experiences in banking and finance. Mr. Mao worked in multiple banks from 1996 to 2010, including Citibank (China) Co. Ltd. Shanghai Branch from December 1996 to March 2005, Societe Generale Asia Limited from April 2005 to May 2007, the Deutsche Bank AG, Hong Kong Branch from May 2007 to July 2009, and Zhong De Securities Co. Ltd. from August 2009 to July 2010. He worked at Citigroup Global Markets Asia Limited as the managing director of Hong Kong Capital Markets Coverage, from July 2010 to July 2024. He has been serving as an independent director of China Life Insurance (Overseas) Company Limited since February 2025, and a panel member of the Mandatory Provident Fund Schemes Appeal Board of Hong Kong since October 2025. In addition, he has been serving as a director of Guangzhou EHolly Intelligent Equipment Co. Ltd. since April 2026. Mr. Mao obtained the dual bachelor's degrees in management information systems and technology English from Tianjian University in the PRC in July 1993. He obtained a master's degree in business administration from Fudan University in the PRC in January 2003. Announcement • Mar 31
MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026 MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026. Location: no.501 niudun road, pudong new district, shanghai, China Announcement • Mar 18
MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2025 Results on Mar 30, 2026 MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2025 results on Mar 30, 2026 Announcement • Aug 15
MicroPort CardioFlow Medtech Corporation to Report First Half, 2025 Results on Aug 28, 2025 MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • Jun 27
MicroPort CardioFlow Medtech Corporation Announces Board Changes, Effective June 27, 2025 MicroPort CardioFlow Medtech Corporation announced that Dr. Ding Jiandong (Dr. Ding) retired as an independent non-executive Director with effect from the conclusion of the AGM and did not offer himself for re-election at the AGM as disclosed in the Circular. Accordingly, Dr. Ding ceased to act as a member of each of the audit committee (the Audit Committee) and nomination committee of the Company (the Nomination Committee) with effect from the conclusion of the AGM. Dr. Ding has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange. The Board announced that Dr. Hu Bingshan (Dr. Hu) has been appointed as an independent non-executive Director and a member of each of the Audit Committee and Nomination Committee, with effect from June 27, 2025 following the retirement of Dr. Ding. The biographical details of Dr. Hu are set out: Dr. Hu, aged 43, has successively served as associate professor and professor at the University of Shanghai for Science and Technology since November 2016. His main research field is rehabilitation and nursing robotics. From October 2010 to November 2016, Dr. Hu worked as a space robotics systems engineer at the Shanghai Aerospace System Engineering Institute in the China Aerospace Science and Technology Corporation. In 2015, he also served as a visiting scholar at the University of Hamburg in Germany. Dr. Hu serves as a committee member for the Sports Health and Industry Promotion Committee of China Association of Rehabilitation Medicine and other relevant academic organizations. He received the First Prize and the Second Prize of Science and Technology from the China Association of Rehabilitation Medicine in October 2023 and in September 2024, respectively. Dr. Hu has published more than 50 papers in internationally recognized journals or academic conferences. He is also an inventor or co-inventor of more than 70 Chinese and overseas patents. Dr. Hu received his bachelor's degree in electrical engineering and automation and his master's degree in power electronics and electric drives from Harbin University of Science and Technology in July 2003 and April 2006, respectively, and obtained his Ph.D. in mechatronic engineering from Shanghai Jiao Tong University in December 2010. Dr. Hu shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company. Announcement • Mar 28
MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025 MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025. Location: no. 1661 zhangdong road, zhangjiang hi-tech park, pudong new district, shanghai China Announcement • Mar 17
MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2024 Results on Mar 27, 2025 MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Mar 27, 2025 Announcement • Aug 15
MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024 MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Mar 29
MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024 MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024. Location: No. 1661 Zhangdong Road, Zhangjiang Hi-Tech Park Pudong New District, Shanghai China Announcement • Mar 16
MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024 MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2023 results on Mar 27, 2024 Announcement • Jan 08
Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System The board of directors of the Company of MicroPort CardioFlow Medtech Corporation announced that, on January 5, 2024, MP CardioAdvent received the approval from the National Medical Products Administration of the People's Republic of China regarding the registration application for AnchorMan left atrial appendage closure system, the self-development product of MP CardioAdvent, which is also the only approved semi-closed type LAAC product in China so far. In addition, it completed the registration application of CE Mark in December 2023. AnchorMan LAAC System comprises a LAA closure and a delivery system, which is applicable for patients with nonvalvular atrial fibrillation with the CHA2DS2-VASC (a stroke risk assessment tool) score 2 and have contraindications in long-term oral anticoagulation therapy or still at risk of stroke after anticoagulation therapy. The major innovative designs of AnchorMan LAAC System include: the semi-closed structure formed by the 12 "3D folding" units and the frame combines the merits of an open and closed closure device, solving the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA, and achieving stable anchoring, the rounded and soft distal end could reduce damage to the LAA tissue; the dense NiTi alloy frame design allows very tight conformity to the anatomy of LAA and achieves better sealing performance; and two deployment models of advancement and unsheathe are available to provide more options for physicians. In addition, AnchorMan LAAC System is available in six closure device diameters ranging from 20 mm to 35 mm for a larger patient population. The NMPA registration approval of the AnchorMan LAAC System enables the Group to expand its business from heart valves to a new segment in the structural heart disease field with large patient population and fast growth rate, which will further expand the Company's revenue stream and enhance its comprehensive competitiveness. Announcement • Oct 26
MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe The board of directors of MicroPort CardioFlow Medtech Corporation announced that the Group's self-developed second-generation transcatheter aortic heart valve implantation ("TAVI") product, VitaFlow Liberty transcatheter aortic valve implantation system, has recently completed seven pre-market clinical implantation cases in Denmark and Ireland. All patients recovered well after the procedures. VitaFlow Liberty is the only self-developed TAVI product in China to conduct clinical trials in Europe, and is expected to become the first Chinese TAVI product to receive CE mark. As the world's first and only motorized retrievable TAVI system, after its registration approval by the China National Medical Products Administration in August 2021, VitaFlow Liberty has been successfully registered in Argentina, Colombia, Thailand and Russia and progressed its CE mark registration in good order. In its nearly 200 cases of overseas commercial applications, VitaFlow Liberty received high praises from overseas physicians for its excellent release stability, precise positioning, optimized perivalvular leakage prevention and hemodynamic performance. The successful advancement of VitaFlow Liberty's pre-market clinical trial will lay a solid foundation for its launch in markets recognizing the CE mark. The Group looks forward to the early approval for the CE mark registration of VitaFlow Liberty and its rapid subsequent commercialization in Europe to bring high quality and universally-accessible solutions to more TAVI patients around the world. Announcement • Oct 17
MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product MicroPort CardioFlow Medtech Corporation announced that the third-generation transcatheter aortic heart valve implantation product independently developed by the Group ("Third-Generation TAVI Product") which is equipped with an upgraded retrievable steerable delivery system was successfully applied by the heart teams of Fuwai Hospital of the Chinese Academy of Medical Sciences and Shanxi Provincial Hospital of Cardiovascular Diseases to treat two patients with severe aortic stenosis. The patients are now recovering well with significant relief of related symptoms. The successful first-in-man applications of Third-Generation TAVI Product marked its entry into the clinical application phase and further enriched TAVI product offering to increase competitiveness. Originated from the Group's deep understanding of clinical needs and pain points, self-developed Third-Generation TAVI Product is an iteration of VitaFlow Liberty®, second-generation TAVI product which is now widely used in TAVI procedures. The delivery system of this product is upgraded with a highly innovative steerable function, which is designed to help cross the aortic arch and the native valve, facilitate the delivery process to achieve less tissue damage, enhance valve coaxiality during pre-positioning and release, make it easier to anchor in the appropriate position, further reduce the maneuver difficulty and increase positioning accuracy, thus improving the procedure success rate and enhancing the therapeutic effects. The unique spatial curvature is more in line with the human heart structure and is suitable for a variety of challenging anatomies. Meanwhile, the limit switch on the handle of the delivery system helps physicians to reduce the rate of intraoperative mishandling and further optimizes the procedure process. The first two successful clinical applications of the Third-Generation TAVI Product is another important milestone of the Group's comprehensive deployment in the field of structural heart disease, and a manifestation of solid technical reserves and innovative research & development capabilities in the field of structural heart diseases. The product impresses physicians with its excellent ease-of-use, more accurate positioning and improved procedure efficiency. look forward to the launch of the Third-Generation TAVI Product as soon as possible to treat more patients with aortic valve disease. Announcement • Aug 18
MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023 MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2023 results on Aug 29, 2023